BPC-157

Plain-English version: BPC-157 is a small protein fragment (a "peptide") that scientists copied from a larger protective compound naturally present in your stomach fluid. The idea researchers have chased for 30+ years is that this fragment carries much of the parent protein's tissue-protecting activity in a stable, easy-to-study form.

"BPC" stands for Body Protection Compound; "157" refers to this specific 15-amino-acid sequence. Its amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (molecular weight roughly 1,419 Da). A notable feature is that it is unusually stable in stomach acid — most peptides are destroyed there — which is why researchers have explored oral as well as injected routes.^[10]

Most of the published literature comes from the laboratory of Professor Predrag Sikiric at the University of Zagreb, Croatia, with a growing number of replications and reviews from other groups. Across those papers, BPC-157 has been described as a "stable gastric pentadecapeptide" with broad, body-wide protective effects in animal models — spanning tendon, ligament, muscle, bone, gut, brain, and blood-vessel injury.^[7]

The credibility caveat, stated up front: breadth of animal research is not the same as proof in humans. A 2026 review summarizing the field concluded that human research "remains limited to small pilot studies" in areas like musculoskeletal pain and interstitial cystitis, with no rigorous controlled trials to validate efficacy.^[10] BPC-157 is not approved for medical use in any country, and on September 29, 2023 the U.S. FDA placed it on the 503A "Category 2" list of bulk substances that "may present significant safety risks," which bars state-licensed compounding pharmacies from making it.^[11] For the full legal breakdown, see Are Peptides Legal?

Takeaway first: BPC-157 does not appear to have one single "on switch." In animal and cell studies it nudges several repair-related systems at once — most clearly, new blood-vessel growth and the nitric-oxide system that controls blood flow. Here is what the verified research actually shows, and where it stops.

1. Angiogenesis — growing new blood vessels (best-supported mechanism)

"Angiogenesis" just means building new blood vessels. New vessels bring oxygen, nutrients, and repair cells to damaged tissue, which is the foundation of healing. In human endothelial cells grown in a dish (in vitro) and in rats with a blocked hind-limb artery, BPC-157 activated and up-regulated the VEGFR2 receptor, feeding the VEGFR2-Akt-eNOS signaling cascade, and it sped up blood-flow recovery while increasing the number of vessels.^[4] A broader review concluded BPC-157 behaves as a potent "angiomodulatory" agent across several vascular-injury models.^[5] Evidence level: cell culture plus rats — not humans.

2. Nitric-oxide (NO) system modulation

Nitric oxide is a molecule your body uses to widen blood vessels and manage blood pressure and mucosal protection. What is interesting is that BPC-157 seems to work in both directions: in rats it counteracted the effects of L-NAME (a drug that blocks NO) and also counteracted L-arginine (which pushes NO up), helping keep the stomach lining and blood pressure in balance.^[6] That bidirectional, "steadying" behavior is proposed to explain why it shows protective effects in so many different injury settings. Evidence level: rats.

3. Growth-factor and tendon-cell signaling

In cultured rat tendon fibroblasts (tendon-building cells), BPC-157 increased growth-hormone-receptor expression in a dose- and time-dependent way, both at the gene (mRNA) and protein level — a proposed route to better tendon healing.^[3] This is a plausible piece of the "why tendons respond" puzzle, but again it is in vitro cell work, not a human outcome.

4. Gut-brain axis (theoretical / hypothesis-generating)

Because BPC-157 originates in the gut yet shows effects on the nervous system in animals, reviewers have proposed it as a candidate mediator of "brain-gut" communication, including interactions with the dopamine and serotonin systems.^[7] This is the least settled area: treat it as an interesting hypothesis built on animal data, not an established mechanism. Do not read it as evidence BPC-157 treats any neurological or mood condition.

What we do NOT know

There is no confirmed human receptor target and no human dose-response data. Absorption and clearance have been measured, but only in animals — see how long BPC-157 stays in the body for the actual numbers. The mechanisms above are real published findings, yet they are almost entirely from rats and cell cultures, and mechanism in animals does not guarantee benefit in humans.

Straight answer: yes, but barely — and not in a way that proves it works. Three small human studies have been published. None was randomized. None had a placebo group. All three came out of private clinics, all three share an author, and all three appeared in the same low-tier journal.^[14] That is the entire human record.

The three human studies, named

Study	People	What was done	Result
Intravenous safety pilot (2025)	2	10 mg on day 1, then 20 mg on day 2, by IV drip	No side effects; no measurable change in heart, liver, kidney, thyroid, or blood-sugar markers[15]
Interstitial cystitis pilot (2024)	12 women	10 mg injected into the bladder wall during a single cystoscopy	10 of 12 reported complete symptom relief, 2 reported ~80%; no adverse events[16]
Knee pain chart review (2021)	16 reached (of 17)	Injected into the knee joint, alone or with TB-500; patients phoned months later	14 of 16 (87.5%) reported pain relief[17]

Why we are not calling this proof

Read those results and the temptation is to conclude it works. Here is why a careful reader should not, yet:

• No control group. Nobody got a placebo. Pain and bladder symptoms both improve on their own and both respond strongly to placebo, so there is no way to separate the peptide from the effect of being treated.
• The knee study asked people to remember. It was a look back through charts, with patients phoned 6-12 months later and asked to rate pain they had months ago. Memory is not a measurement.
• Two people is not a safety study. The IV pilot is genuinely useful — it is the first human dosing data of any kind — but two participants cannot detect a side effect that happens in 1 of 100 people.
• Same author, same journal, same clinic. Independent replication is what turns a promising result into a fact, and it has not happened.

So the honest summary stands: no completed randomized controlled trial of BPC-157 exists in humans. What exists is three small, uncontrolled reports that found no harm and suggested benefit. That is a reason to run a real trial, not a reason to believe the question is settled.

Benefits and side effects, in one paragraph: in animals, BPC-157 consistently helps tendons, ligaments, gut lining, nerves, and blood vessels repair faster and more neatly — that is the benefit, and it is real but preclinical. Against that, the reported side effects are mild and mostly limited to injection-site irritation and occasional nausea, with a formal animal toxicology study finding no serious toxicity across four species. The catch is not a scary side effect; it is the missing evidence. No randomized human trial has ever been completed, so nobody can tell you the size of the benefit or rule out a rare harm. Full side-effect and safety detail is here.

How to read this section: for each area we give the plain-English claim, the proposed mechanism, the population actually studied, the observed effect, and the limitation. Nearly every result below is from rats or cell cultures. That does not make it worthless — it makes it preliminary. Anecdotal human reports exist but are not controlled evidence.

Tendon healing

Claim: may help injured tendons repair with better-organized tissue. Mechanism: angiogenesis plus up-regulated growth-hormone-receptor signaling in tendon cells. Population: rats with a surgically transected (fully cut) Achilles tendon, plus tendon cells in vitro. Effect: BPC-157 improved healing with better collagen-fiber organization and more type-I collagen, and stimulated tendon-cell (tendocyte) growth in the dish.^[1][3] Limitation: these are animal and cell results; the widely repeated "2-3x faster" figure is not a stated number in the source and should not be taken as established. Tendon healing is BPC-157's single most-cited use case, which is exactly why it drives so much of the healing and joint health interest. For the full, evidence-graded breakdown by injury type — does BPC-157 actually heal injuries, graded honestly — including the first human RCT now recruiting, see our dedicated review.

Ligament healing

Claim: may support ligament repair after injury. Mechanism: improved local blood supply and collagen organization. Population: rats with a surgically transected medial collateral ligament (MCL) followed for 90 days. Effect: BPC-157 (studied as PL-14736) improved MCL healing versus untreated controls.^[2] Limitation: single injury model, rodents only; no human ligament data.

Gut protection and healing

Claim: may protect and heal the digestive-tract lining. Mechanism: cytoprotection of mucosa plus angiogenesis, consistent with its origin in gastric juice. Population: rats with chemically induced colitis and with surgically joined bowel segments (colon-colon anastomosis) that otherwise failed to heal. Effect: low doses (10 µg/kg and 10 ng/kg, given into the abdomen or in drinking water) healed the colitis and the anastomosis, and in the same line of work reduced cuprizone-induced brain injury and motor disability in a multiple-sclerosis-type model.^[8] Limitation: rodent models; oral human bioavailability and effective human doses are not established. This gut-repair angle is why BPC-157 is often discussed alongside KPV for gut inflammation.

Nerve and spinal-cord injury

Claim: may aid recovery after nervous-system injury. Mechanism: neuroprotection plus improved local vascular support. Population: rats with spinal-cord compression injury. Effect: a single dose (200 or 2 µg/kg) given 10 minutes after injury produced consistent motor recovery, resolved spasticity by day 15, and left less microscopic white- and grey-matter damage, with benefits tracked out to 360 days.^[9] Limitation: a single acute-injury rodent model; do not extrapolate to human spinal-cord or neurological disease.

Blood vessels and circulation

Claim: may improve blood supply to injured or ischemic tissue. Mechanism: VEGFR2-driven angiogenesis and NO-system balancing. Population: human endothelial cells in vitro and rats with limb ischemia or vascular-injury models. Effect: faster blood-flow recovery, more new vessels, and angiomodulatory activity across models.^[4][5] Limitation: cell and rodent data only.

The honest bottom line on "benefits"

• No human clinical trials have been completed. Human pharmacokinetics, effective doses, and long-term outcomes are unknown.^[10]
• Research is concentrated. A large share of studies come from one research group; independent replication, while growing, is still limited.
• Publication bias means positive animal results are more likely to be published than null ones.
• Anecdotes are not data. Enthusiastic user reports cannot substitute for controlled trials.

Short answer: not long. In the only published pharmacokinetic study, BPC-157's elimination half-life was under 30 minutes in both rats and beagle dogs, across intravenous and intramuscular routes.^[12] "Half-life" just means the time it takes for half of the dose to clear your bloodstream.

This matters because you will frequently see "4-6 hours" quoted as BPC-157's half-life on vendor sites and forums — including, until this update, in some tables on this site. We could not find a primary source for that figure, and the measured one is roughly ten times shorter. We corrected it rather than repeat it.

What the study actually measured

Measure	Finding	Species
Elimination half-life	Under 30 minutes	Rats and beagle dogs
Bioavailability (intramuscular)	~14-19%	Rats
Bioavailability (intramuscular)	~45-51%	Beagle dogs
Route of clearance	Urine and bile	Rats
Fate in the body	Broken down into small peptide fragments, then into ordinary amino acids	Rats

Why a short half-life does not automatically mean it does nothing

A peptide can clear quickly and still start a process that outlasts it. BPC-157's proposed effects — new blood-vessel growth, collagen organization — are slow tissue changes that take days to weeks, and they do not require the peptide to still be circulating. So a 30-minute half-life is not evidence against it. What it does do is undercut the common claim that one daily injection maintains a steady blood level: on this data, it does not. That is the honest reason most protocols split the dose, though no human trial has tested any schedule.

The caveat that applies to all of it: these numbers are from rats and dogs. Human pharmacokinetics for BPC-157 have never been published, so nobody can tell you the half-life, the bioavailability, or the right dosing interval in a person.

Read this first: there is no clinically validated human dose for BPC-157, because no human dosing trials have been completed. Published protocols are almost all in rats, clustering around 10 µg/kg (and sometimes 10 ng/kg) given into the abdomen or in drinking water.^[8] The 250-500 mcg/day figures circulating online are human extrapolations from animal data, not trial-derived doses. We describe them here for completeness and harm reduction, not as medical guidance.

Commonly cited research protocols (extrapolated, not validated)

Route	Commonly cited dose	Frequency	Typical target	Note
Subcutaneous (systemic)	250-500 mcg	1-2x daily	General/systemic recovery	Abdominal fat pad
Subcutaneous (local)	250-500 mcg	1-2x daily	Specific injury (tendon, joint)	As near the injury as practical
Oral	250-500 mcg	1-2x daily	Gut-focused use	Empty stomach; gastric-acid stable

Route logic in plain terms: for gut targets, oral makes direct contact with the digestive lining and takes advantage of BPC-157's unusual acid stability. For a localized injury, injecting subcutaneously near the site raises local concentration while still allowing systemic absorption. Some protocols use both at once.

"Stable in stomach acid" does not mean "absorbed when swallowed"

This is the most common mix-up in the entire BPC-157 conversation, and a lot of capsule marketing depends on it.

Surviving stomach acid is real and genuinely unusual for a peptide. But surviving your stomach only means the molecule reaches your intestine intact. Getting from the intestine into your bloodstream is a separate step, and then surviving the first pass through the liver is a third. Being acid-stable clears the first hurdle and tells you nothing about the other two.

Here is the part worth knowing: the only bioavailability figures ever measured for BPC-157 come from intramuscular injection — roughly 14-19% in rats and 45-51% in dogs. That study had no oral arm at all.^[12] No published number tells you what fraction of a swallowed BPC-157 capsule reaches your blood, in any species, let alone in a person. Anyone quoting an oral bioavailability percentage is making it up.

None of this means oral is pointless. For a gut problem, the target is the digestive lining, so local contact may be the whole point and absorption into the blood may not matter much. But if your goal is a tendon in your shoulder, swallowing it rests on a step nobody has measured.

Reconstitution math, with a worked example

BPC-157 ships as a lyophilized (freeze-dried) powder that must be mixed with bacteriostatic water before use. The core formula:

Concentration (mg/mL) = vial amount (mg) ÷ water added (mL)

Worked example: take a 5 mg vial and add 2 mL of bacteriostatic water. That gives 5 ÷ 2 = 2.5 mg/mL, i.e. 2,500 mcg per mL. To draw a 250 mcg dose: 250 ÷ 2,500 = 0.10 mL, which is 10 units on a standard 100-unit insulin syringe. A 500 mcg dose is 0.20 mL, or 20 units.

Vial	BAC water	Concentration	250 mcg	500 mcg
5 mg	2 mL	2.5 mg/mL	0.10 mL (10 units)	0.20 mL (20 units)
5 mg	1 mL	5.0 mg/mL	0.05 mL (5 units)	0.10 mL (10 units)
2 mg	1 mL	2.0 mg/mL	0.125 mL (12.5 units)	0.25 mL (25 units)

Preparation steps: wipe the vial stopper with alcohol; draw the water; inject it slowly down the inside wall rather than blasting the powder; swirl gently (do not shake) until fully dissolved; label the vial with the date and concentration. Use the peptide calculator and bacteriostatic water calculator to check volumes, and the reconstitution guide for a step-by-step walkthrough.

Cycle length and timing

• Typical cycle: protocols commonly run 4-6 weeks, with 6-8 weeks used for more chronic complaints. These durations come from convention and animal work, not human trials.
• Timing: injectable BPC-157 has no strict meal timing. Oral is usually taken on an empty stomach for maximum mucosal contact.
• Splitting: twice-daily dosing is used to keep levels steadier; no loading dose or taper is described in the literature.

None of the above should be read as a recommendation to self-administer an unapproved compound. It is a description of how the research doses are structured.

Straight talk: in the small human pilot experiences reported to date, no major adverse effects have been described, and animal data suggest a generally favorable safety and pharmacokinetic profile — but there are no controlled human safety trials, so this is reassurance, not proof.^[10] A recurring, under-appreciated risk is product quality: unregulated research vials vary widely, and impurities can cause effects that get blamed on the peptide itself.

Reported side effects (mostly from user experience, not trials)

Effect	Frequency	Severity	Notes
Injection-site redness/irritation	Common	Mild	Transient; typical of subcutaneous injections
Injection-site swelling	Occasional	Mild	More common with intramuscular use
Mild nausea (oral)	Occasional	Mild	Usually in the first few doses
Lightheadedness	Rare	Mild	Possibly NO/blood-pressure related
Headache	Rare	Mild	Transient

What the formal toxicology study found

There is one dedicated preclinical safety study, run across mice, rats, rabbits, and dogs.^[13] Its findings, stated plainly:

• A single dose produced no effects attributable to the compound.
• On repeated dosing, dogs tolerated it with no abnormal changes versus controls — with one exception: a drop in creatinine at the highest dose (2 mg/kg), not seen at lower doses. The animals recovered on their own within two weeks of stopping.
• Local irritation at the injection site was mild.
• No genetic toxicity and no harm to developing embryos.

That creatinine finding is the one real signal in the data, and we would rather point at it than pretend the study was spotless. Creatinine is a marker doctors use to watch kidney function. It went down, not up, it happened only at a dose far above anything discussed for human use, and it reversed. It is not evidence of kidney damage — but it is a measured change in an organ marker, and you should know it exists.

One correction to what you will read elsewhere: sites routinely claim BPC-157 has "no established LD50" and a "negative Ames test." That study says neither of those things. What it supports is the sentence above — well tolerated, no serious toxicity, in four animal species.

The theoretical risks worth understanding

Reviewers who take BPC-157 seriously still flag three mechanism-based concerns. None has been observed as harm in a person; all three follow logically from how the peptide is thought to work.^[14]

• Blood-vessel growth in the wrong place. The same angiogenesis that helps a tendon heal is a process tumors and some inflammatory diseases also use.
• A metabolite worth watching. One of the main things BPC-157 breaks down into is proline, an ordinary amino acid that in some settings contributes to the production of reactive molecules that can damage other cell components.
• Too much nitric oxide, and the drug-interaction problem nobody explains. This is the one to actually understand. At high levels, nitric oxide interferes with how the body inserts heme (the iron-carrying part of red blood cells) into proteins, and it changes the activity of the CYP enzymes — the liver's main system for clearing medications. Those effects are linked to anemia and to altered drug metabolism. In plain terms: in theory, this could change how fast your body processes other drugs you take. That is a concrete reason to tell a doctor, not a vague "consult your physician."

Theoretical risks and who should avoid it

• Active cancer — and the argument on the other side. Because BPC-157 promotes new blood-vessel growth, the obvious worry is that it could feed a tumor's blood supply. That worry is legitimate and it is why the answer below is still "avoid." But the evidence does not all point one way, and it would be dishonest to show you only half of it: in published work BPC-157 has also been shown to inhibit uncontrolled cell growth, turn VEGF signaling down rather than up, and counteract VEGF-driven tumor development.^[14] It appears to push angiogenesis up or down depending on the tissue it is in. So the state of play is genuinely unresolved, with findings in both directions and no human data at all. The practical advice does not change: anyone with active or recent cancer should stay away until this is studied directly, because "unresolved" is not a risk worth taking with a tumor.
• Pregnancy and breastfeeding: no reproductive-safety data exist — avoid.
• Active infection: its immune-modulating effects could in theory blunt pathogen clearance; unstudied.
• Anticoagulant or blood-pressure medication users: given its vascular and NO-system activity, additive effects are plausible but formally uncharacterized — a reason for medical oversight, not self-experimentation.

The limitations you must keep in mind

• Most safety data are from rats, from a limited number of research groups.
• No completed human trials means human pharmacokinetics, drug interactions, and long-term safety are unknown.
• Human reports are uncontrolled and prone to bias.
• Contaminants from low-quality product are a real and separate hazard.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Is BPC-157 a supplement?

No — and this is the single most misunderstood fact about it. BPC-157 is not a dietary ingredient. It is an unapproved drug, and it cannot legally be prescribed or sold over the counter in the United States.^[18] It does not appear in the FDA's approved-drugs database under any of its names.

You will nevertheless find it sold in capsules and "health and wellness" products, which is exactly why people search for it as a supplement. Those products are typically labeled "research use only" or "not for human consumption" — wording that exists to keep the seller on the right side of a line, not to describe how customers actually use it. The U.S. Department of Defense puts BPC-157 on its Prohibited Dietary Supplement Ingredients List, and service members are told to avoid it in any form, swallowed or injected.^[18]

You may also see it under other names: BPC-15, PL-10, PLD-116, PL 14736, and Bepecin. Same compound, same status.

A word on "Pentadeca Arginate" (PDA)

Capsules are increasingly sold as BPC-157 "arginate" rather than the usual acetate form, with the claim that the arginate salt is more stable or better absorbed by mouth. We went looking for the evidence behind that claim and could not find any. There is no published pharmacokinetic study of a BPC-157 arginate salt, and the peer-reviewed literature on BPC-157 formulation does not discuss arginate at all. Every source making the claim is selling the product.

That does not prove arginate is worthless — absence of evidence is not evidence of absence. It does mean the superiority claim is marketing, not science, and you should not pay a premium for it on the strength of a vendor's word.

Will BPC-157 show up on a drug test?

If you are a tested athlete: yes, it is detectable, and it is banned. Anti-doping laboratories have had a validated urine test since 2017, sensitive down to 0.1 ng/mL, and BPC-157 stays detectable in urine for at least four days.^[19] "It's just a peptide, it clears fast" is not a defense — the short half-life described above does not make it invisible, because the test looks for a stable breakdown product too.

We have no source on whether BPC-157 appears on standard workplace drug panels, so we are not going to guess. Those panels look for a specific list of drugs of abuse and BPC-157 is not among them, but we cannot cite that, so treat it as unverified.

Why the rest of this section matters: BPC-157 is an unregulated research compound, so purity and identity vary enormously between suppliers. For an unproven peptide, contamination is arguably a bigger practical risk than the peptide itself. Knowing how to read a Certificate of Analysis (COA) is the single most useful skill here.

What a credible product should show

• Third-party COA: independent HPLC purity testing (look for ≥98%) plus mass-spectrometry identity confirming the expected molecular weight (~1,419 Da).
• Batch-specific results: the COA should reference the exact lot you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial.

Red flags

• No COA, or a COA from the seller rather than an independent lab
• Pre-mixed liquid "ready to use" peptide (shorter shelf life, contamination risk)
• Prices far below the market
• Explicit human-use or medical claims, which signal a non-compliant, higher-risk vendor

Legal and regulatory status (2026)

• Not FDA-approved for any use, in any country.^[11]
• 503A Category 2 since September 29, 2023: the FDA lists BPC-157 among bulk substances that "may present significant safety risks," which prevents state-licensed compounding pharmacies from making it. The agency cited immunogenicity concerns for some routes, peptide-impurity/characterization complexity, and little safety data for the proposed routes.^[11]
• July 2026 — advisory panel recommended re-adding it: on July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend adding BPC-157 to the 503A list, overruling the FDA's own scientists. This is a non-binding recommendation, not an approval — it does not change BPC-157's status on its own, and legal compounding would still require FDA rulemaking — a process whose track record runs in years, not months. See our July 2026 FDA peptide panel vote report.
• Not a controlled substance: BPC-157 is not DEA-scheduled; possession is not criminalized.
• Sport: banned by WADA. BPC-157 is named explicitly in the S0 (Non-Approved Substances) class of the 2026 Prohibited List, which reads: "This class covers many different substances including but not limited to BPC-157." S0 substances are prohibited at all times, in and out of competition.^[20] If you are tested by WADA, USADA, or a national federation, there is no version of this you can run. A future compounding pathway would not change that.

Storage

Keep unopened lyophilized vials cold and dark (freezer or refrigerator). Once reconstituted, refrigerate at 2-8°C and use within a few weeks; never freeze a reconstituted solution, and discard anything cloudy or discolored. See the full peptide storage guide. For the complete legal picture, read Are Peptides Legal?

BPC-157 is usually weighed against a few neighbors. None of these comparisons are backed by head-to-head human trials — they contrast proposed mechanisms and the animal literature.

BPC-157 vs. TB-500

Factor	BPC-157	TB-500
Proposed mechanism	Angiogenesis, NO modulation, growth-factor signaling	Actin regulation, cell migration, anti-inflammation
Often used for	Tendons, ligaments, gut, localized injury	Systemic recovery, muscle, flexibility
Oral option	Explored, because it survives stomach acid — but oral absorption has never been measured	No — injection only
Combined?	Frequently paired in the Healing Stack for complementary coverage

Read the full BPC-157 vs TB-500 comparison.

BPC-157 vs. GHK-Cu

GHK-Cu is primarily a skin, anti-aging, and hair peptide (copper delivery and broad gene modulation), whereas BPC-157 is oriented toward musculoskeletal and gut repair. They target different problems more than they compete. See the BPC-157 vs GHK-Cu comparison.

BPC-157 vs. KPV

Both are studied for gut inflammation but differ in emphasis: BPC-157 leans toward mucosal repair and cytoprotection, while KPV (an alpha-MSH fragment) is a more targeted anti-inflammatory. Some gut protocols pair them.

Quick answer: research-grade BPC-157 usually runs about $40-80 for a 5 mg vial. At a commonly cited 250 mcg/day, one 5 mg vial covers roughly 20 days, so a typical 4-6 week protocol needs one to two vials plus consumables.

Item	Typical cost
5 mg vial (research grade)	$40-80
Bacteriostatic water	$8-15
Insulin syringes (box)	$10-15
Full 4-6 week protocol	~$60-175

Oral capsules are generally more expensive per dose than reconstituted injectable vials. Remember that price should never be the deciding factor over a verifiable third-party COA — a cheap, untested vial is the most expensive mistake you can make with an unregulated compound.